Patients with NSCLC CNS metastasis harboring EGFR mutations have a great response to EGFR tyrosine kinase inhibitor (TKI) treatment with RRs of 60–80% (OS 15–20 months) [20,21]. Here, EGFR is linked to non-small cell lung carcinoma.